Therefore, we evaluated the correlation between sMICA/B with the OS and progression-free survival (PFS) in a cohort of 29 stage-IV melanoma patients treated with pembrolizumab (anti-PD-1 mAb). The gene discussed is PDCD1; the disease is melanoma.